AbClon Pipeline
Advanced antibody platforms revolutionizing treatments for cancer and other previously incurable diseases.
AbClon
AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development.
Our mission is to cure once incurable diseases such as cancer.
CAR-T
CAR T-cell (Chimeric Antigen Receptor) therapy is the state-of-the-art gene cell therapy that is ushering in the age of personalized medicine.
It boasts superior treatment effectiveness and lower side effects by programming the patient's own immune cells to target tumor cells.
The first generation of CAR-T treatments have already demonstrated major leaps in the treatment of patients with hematologic cancers such as leukemia and lymphoma.
AbClon's CAR-T program incorporates the next-gen technologies of CAR-T by integrating with NEST, zCAR-T, and Affibody platforms.
Learn more about AbClon's revolutionary CAR-T technology and how it's transforming cancer treatment
NEST
Antibody drugs act specifically on the target proteins responsible for the disease and as a result have high efficacy and low side effects.
AbClon's development of the NEST (Novel Epitope Screening Technology) platform was made possible through its experience in developing tens of thousands of antibodies.
AffiMab
Bispecific antibodies can achieve stronger therapeutic effects by simultaneously acting on two different target proteins.
AbClon's AffiMab platform allows for easy development of bispecific antibodies by incorporating Affibody technology.
Affibodies are alternative capture molecules one-fifth the size of antibodies that are affixed to regular antibodies to give it bispecific targeting capability.
The AffiMab platform has been integral towards AbClon's development of various anti-cancer and autoimmune therapeutics.
YOUR HOPE WE KEEP
AbClon will strive to safeguard everyone's health and hope.
AbClon will take the lead in the development of treatments for intractable diseases based on innovative drug development platforms and its extensive experience in antibody therapeutics development.